THE NATIONAL INSTITUTE OF HEALTH AND CARE, England, recommended Eribulin for the treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimen for advanced disease. In the European Union, The DRUG is indicated as at least one chemotherapeutic regimen and marketing authorization was granted in 2014....
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
